Payback Time For Lilly? Erbitux Follow-on Succeeds In Squamous Lung Cancer Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly’s necitumumab – gained through the company’s ImClone acquisition – demonstrates an overall survival benefit in the SQUIRE study against first-line metastatic squamous NSCLC. Pleasantly surprised by the outcome, some analysts start to expect blockbuster sales.
You may also be interested in...
Melanoma Success Paves Way For Path Of Gold In Cancer Immunotherapy
Phase I data for immune checkpoint molecules in melanoma from Bristol, Roche and Merck were a major highlight of the ASCO 2013 annual meeting. Considering potential application in many cancers regardless of genetic mutations, some analysts are predicting billions in future sales.
Ramucirumab Becomes First Lilly ImClone Compound To Enjoy Phase III Success
The VEGF2-inhibitor demonstrated an overall survival benefit and prolonged progression-free survival in second-line gastric cancer, Lilly said. The big pharma acquired ramucirumab through its $6.5 billion purchase of ImClone Systems in 2008.
Blood Clot Risk Causes Lilly, Bristol To Halt Enrollment In Erbitux Follow-On Trial
Safety concern occurs about one year after the two companies resolved rights dispute over antibody arising from Lilly/ImClone merger.